David Tuller
Trial By Error: A Letter Requesting Corrections of Inflated Prevalence Rates in Nine More FND Papers
By David Tuller
By David Tuller, DrPH Several colleagues and I recently wrote to the journal NeuroImage: Clinical to request a correction in a 2021 article about functional neurological disorder (FND). The article included the false claim that a seminal 2010 study found that FND was the second-most-common diagnosis at outpatient neurology clinics. ...
Trial By Error: Families with Long Covid Kids Fight Against Medical/Social Services
By David Tuller
By David Tuller, DrPH For decades in the UK, parents of children with what was formerly called chronic fatigue syndrome have run the risk of being accused of making or keeping their kids sick and/or not pursuing proper treatment strategies. These cases have been based on the discredited belief that ...
Trial By Error: FND Experts Agree To Correct Inflated Prevalence Claim
By David Tuller
By David Tuller, DrPH For years, experts in functional neurological disorder (FND) have cited a seminal study in their field to claim that the diagnosis was the second-most-common presentation at outpatient neurology clinics, with a prevalence of 16%. This claim was, and is, categorically untrue. The Scottish Neurological Symptoms Study ...
Trial By Error: Action For ME Report on NICE Guidelines; Brian Hughes on Myths About the Guidelines; Michael Sharpe’s San Francisco Speech
By David Tuller
By David Tuller, DrPHI often feel so far behind in keeping up with developments in this field. Here are a few recent items I wanted to highlight.**********Action For ME's report on NHS adoption of the new NICE guidelines In October, 2021, after a protracted and highly contentious process, the UK’s ...
Trial By Error: Claim that CBT Is Safe Is “Misleading,” Says Dutch Ad Group
By David Tuller
By David Tuller, DrPH In a recent decision, the Advertising Code Foundation in the Netherlands has criticized as “misleading” a statement on the website of the Knowledge Center for Chronic Fatigue (NKCV) touting its treatment approach as “not harmful.” The decision is something of a slap at the NKCV and ...
